Seribantumab  (Synonyms: SAR 256212; MM 121)

Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models^[1].

Human IgG2 lambda

Human IgG2 lambda, Isotype Control

Human

ERBB3/HER3

Seribantumab (0.1 nmol/L-10 μmol/L; 96 h) dose-dependently inhibits two cell lines that harbor NRG1 rearrangements (MDA-MB-175-VII, DOC4-NRG1 fusion and LUAD-0061AS3, SLC3A2-NRG1 fusion) with IC₅₀ values of 0.02, 1.4, 45.2 and 203 μmol/L for MDA-MB-175-VII, LUAD-0061AS3, MCF-7 and HBECp53 cells, respectively^[1].
Seribantumab (0.1, 1, and 10 μmol/L; 24-48 h) effectively inhibits growth of tumor cell lines that harbor NRG1 fusions or NRG1 amplification^[1].
Seribantumab (0-0.5 μmol/L; 96 h) largely suppresses growth of NRG1-b1-stimulated MCF-7 cells^[1].
Seribantumab (0-10 μmol/L; 48 h) induces apoptosis of cells harboring NRG1 rearrangements^[1].
Seribantumab (0-10 μmol/L; 1 h) inhibits phosphorylation of downstream mediators in cells with NRG1 alterations^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Seribantumab (0.6-1 mg; i.p. twice weekly for once) reduces tumor growth in non-small cell lung cancer (NSCLC) patient-derived xenograft (PDX) mice model with a higher efficacy than afatinib, blocks phosphorylation of growth modulators and induces expression of apoptosis markers in vivo^[1].
Seribantumab (1-10 mg; i.p. twice weekly for once) eliminates the vast majority of tumor cells and causes no significant change in overall animal health or weight in High-grade serous ovarian cancer (HGSOC) mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2065  [NCBI]

P21860

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.14 kDa

1334296-12-6

Liquid

Colorless to light yellow

[Seribantumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 lambda

• 
  Immobilized HER3 Protein, Human (HEK293, His, HY-P72625) can bind Seribantumab. The EC₅₀ for this effect is 7.53 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ MCF-7 cells labeling Seribantumab (HY-P99268, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 lambda (HY-P991206, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Odintsov I, et al. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. Clin Cancer Res. 2021 Jun 1;27(11):3154-3166.  [Content Brief]